2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care

2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care

Against the vibrant autumn backdrop of Nanjing, breast cancer experts gathered on October 11, 2026, for the 2026 East China Breast Cancer Salon. Under the theme “Ninety Years of Compassion and Dedication, Passing the Torch of Medical Excellence,” the meeting focused on advances in breast cancer diagnosis and treatment, clinical implementation, and the development of the specialty. Over the past decade, the salon has established a strong regional foundation while benchmarking its work against international standards, creating an academic platform that integrates cutting-edge research, clinical application, and professional training.
ESMO Preview | ORR of 68% and Median PFS of 11.2 Months: A New First-Line Strategy for la/mUC With Sacituzumab Tirumotecan Plus Immunotherapy

ESMO Preview | ORR of 68% and Median PFS of 11.2 Months: A New First-Line Strategy for la/mUC With Sacituzumab Tirumotecan Plus Immunotherapy

With advances in clinical research and updates to treatment guidelines, antibody–drug conjugate (ADC) combinations with immunotherapy have become a new standard of first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). The 2026 Congress of the European Society for Medical Oncology (ESMO) will be held in Madrid, Spain, from October 23 to 27, local time, featuring numerous cutting-edge studies in genitourinary oncology. Among them, data from a study of sacituzumab tirumotecan (Sac-TMT), a TROP2-targeted ADC developed in China, in first-line advanced urothelial carcinoma have been selected for a rapid oral presentation [1]. Updated results showed a confirmed objective response rate (ORR) of 68%, a median duration of response (DOR) of 19.4 months, and a median progression-free survival (PFS) of 11.2 months. Effective and durable tumor responses were observed regardless of patients' TROP2 and PD-L1 expression levels, suggesting a potential new treatment option for this population. The full text of the regular abstract has now been released. This article summarizes the latest developments and key findings for our readers.
Professor Yonghong Li: New Edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment Released, With ADT Remaining the Cornerstone of Comprehensive Disease Management

Professor Yonghong Li: New Edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment Released, With ADT Remaining the Cornerstone of Comprehensive Disease Management

Prostate cancer is one of the most common malignancies threatening men's health. In China, a high proportion of patients are diagnosed at the locally advanced or advanced stage, and overall outcomes continue to lag behind those in developed countries. Improving the overall effectiveness of prostate cancer treatment requires a systematic approach to standardizing and harmonizing diagnosis and treatment nationwide, with quality control for individual diseases serving as a key entry point. Since its establishment in 2021, the Prostate Cancer Quality Control Expert Committee of the National Cancer Center has systematically advanced the development of a quality control framework. The new edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment (hereafter, the Quality Control Yearbook) was recently released. In an interview with Oncology Frontier, Professor Yonghong Li of Sun Yat-sen University Cancer Center shared her insights into prostate cancer epidemiology, the foundational role of androgen deprivation therapy (ADT), the standardized use of treatments and clinical indicators, and future directions for quality control.
SIBCS 2026 | Professor Jian Zhang: From Adjuvant CDK4/6 Inhibitors to Post-Recurrence Treatment—New Perspectives on Stratified Management of HR+/HER2− Advanced Breast Cancer

SIBCS 2026 | Professor Jian Zhang: From Adjuvant CDK4/6 Inhibitors to Post-Recurrence Treatment—New Perspectives on Stratified Management of HR+/HER2− Advanced Breast Cancer

The 21st Shanghai International Breast Cancer Symposium (SIBCS) was held in Shanghai on October 16–17, 2026. The meeting brought together experts in breast cancer from across China for in-depth discussions on comprehensive breast cancer management and precision, stratified treatment.
From Tumor Metabolic Reprogramming to Immune Evasion: Metabolic Immune Checkpoints Offer a New Framework for Precision Immunotherapy

From Tumor Metabolic Reprogramming to Immune Evasion: Metabolic Immune Checkpoints Offer a New Framework for Precision Immunotherapy

On October 9, 2026, a research team from Zhongnan Hospital of Wuhan University, the Taikang Center for Life and Medical Sciences at Wuhan University, the National Cancer Center, and the Cancer Hospital of the Chinese Academy of Medical Sciences published a review article online in Signal Transduction and Targeted Therapy (impact factor: 81.2), entitled “Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.” The review was co-corresponding-authored by Academician Qianjun Xu, Professor Xiehua Xie, and Professor Yechun Yi. It systematically examines the molecular mechanisms through which tumor metabolic reprogramming drives immune evasion and proposes a theoretical framework centered on metabolic immune checkpoints (MICs), offering a new conceptual basis for understanding immunotherapy resistance and developing combined metabolic and immunotherapeutic strategies.
18th Shanghai Breast Reconstruction Conference | Professor Jill Dietz: Lifelong Learning in Oncoplastic Surgery, with MDT Collaboration and Intergenerational Knowledge Transfer as Keys to Progress

18th Shanghai Breast Reconstruction Conference | Professor Jill Dietz: Lifelong Learning in Oncoplastic Surgery, with MDT Collaboration and Intergenerational Knowledge Transfer as Keys to Progress

The 18th Shanghai Breast Reconstruction Conference was held in Shanghai on October 14–15, 2026. The meeting brought together renowned experts from the United States, France, Australia, Germany, the United Kingdom, and other countries and regions to share advanced experience and the latest research in breast reconstruction, specialist training, and interdisciplinary collaboration.
18th Shanghai Breast Reconstruction Conference | Professor Jiong Wu: Focusing on Cutting-Edge Techniques and International Collaboration to Advance Breast Reconstruction

18th Shanghai Breast Reconstruction Conference | Professor Jiong Wu: Focusing on Cutting-Edge Techniques and International Collaboration to Advance Breast Reconstruction

The 18th Shanghai Breast Reconstruction Conference, jointly organized by the Shanghai Anti-Cancer Association and the Shanghai Foundation for Cancer Prevention and Treatment, guided by the Breast Cancer Committee of the Chinese Anti-Cancer Association, and hosted by Fudan University Shanghai Cancer Center, was held in Shanghai from October 10 to 14, 2026. Under the theme “Global Wisdom, Collaborative Practice,” the conference embraced the principles of innovation, cooperation, and development, presenting a high-level, international, and multidisciplinary academic event.
SIBCS Special Feature | Professor Liang Huang: Oncologic Safety Comes First, with Aesthetic Outcomes as an Added Benefit—Individualized Decisions in Breast-Conserving Surgery and Breast Reconstruction

SIBCS Special Feature | Professor Liang Huang: Oncologic Safety Comes First, with Aesthetic Outcomes as an Added Benefit—Individualized Decisions in Breast-Conserving Surgery and Breast Reconstruction

As more patients with breast cancer seek both oncologic cure and preservation of breast appearance, breast-conserving surgery and breast reconstruction have become increasingly important components of comprehensive breast cancer care. The challenge is to improve aesthetic outcomes and quality of life while maintaining oncologic safety, ensuring effective local control, and minimizing long-term risks. This requires individualized, multidisciplinary surgical decision-making. At the 19th National Breast Cancer Conference and the 21st Shanghai International Breast Cancer Symposium (SIBCS), Professor Liang Huang of Fudan University Shanghai Cancer Center spoke with Oncology Frontier about balancing oncologic safety and aesthetic outcomes in breast-conserving surgery and reconstruction, selecting techniques for Chinese women with distinct breast anatomy, weighing implant-based against autologous tissue reconstruction, and the roles of multidisciplinary team (MDT) collaboration and patient communication.
Ask the Experts | Breast Cancer: Professor Shunrong Li — Is Breast Reconstruction After Surgery “The Finishing Touch” or an Essential Part of Treatment?

Ask the Experts | Breast Cancer: Professor Shunrong Li — Is Breast Reconstruction After Surgery “The Finishing Touch” or an Essential Part of Treatment?

Every October, Breast Cancer Awareness Month, widely known as “Pink Ribbon Month,” returns to raise awareness. Supported by healthcare organizations and public interest groups around the world, this initiative aims to improve public understanding of breast cancer, promote early screening, diagnosis, and treatment, and highlight the importance of long-term quality of life for survivors. With rapid advances in systemic therapies and surgical techniques, the goals of breast cancer treatment have evolved beyond simply prolonging survival to include quality of life and a sense of bodily wholeness. As an important component of comprehensive breast cancer care, breast reconstruction can restore physical appearance while also having a profound impact on patients’ psychological well-being, family relationships, and social functioning.
A Global ADC Industry Milestone: SystImmune and Biotech Company Sichuan Biokin Win a Prestigious World ADC Award

A Global ADC Industry Milestone: SystImmune and Biotech Company Sichuan Biokin Win a Prestigious World ADC Award

On October 14, 2026, the 17th World ADC San Diego conference, currently taking place in San Diego, USA, announced this year's World ADC Awards. Iza-bren (lunvenlatug vedotin; Yizekang®, BL-B01D1), a first-in-class, new-concept bispecific antibody–drug conjugate (ADC) independently developed by Sichuan Biokin Pharmaceutical and currently the world's first and only approved EGFR×HER3 bispecific ADC, was named Best ADC Clinical Impact Winner.